SANA supply chain intelligence for Sana Biotechnology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Sana Biotechnology, Inc. (SANA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 90% | In March 2026, the Company entered into an amended and restated sales agreement with TD Securities (USA) LLC (TD Cowen), acting as sales agent, pursuant to which the Company may offer and sell throug… |
| BEAM | Beam Therapeutics Inc. | 72% | the University of California (UCSF), our fusogen technology that we acquired from Cobalt Biomedicine, Inc. (Cobalt), and gene editing technology that we licensed from Beam Therapeutics Inc., among ot… |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from SANA graph: the University of California (UCSF), our fusogen technology that we acquired from Cobalt Biomedicine, Inc. (Cobalt), … |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from SANA graph: with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property,… |
| MYGN | Myriad Genetics, Inc. | 72% | with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property, the value of such technology, data, or intellectual property to our company may b… |
| SNYNF | Sanofi | 72% | with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property, the value of such technology, data, or intellectual property to our company may b… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from SANA graph: with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MAYO-CLINIC | MAYO-CLINIC | 92% | The Company agreed to sell to Mayo Clinic, and Mayo Clinic agreed to purchase from the Company, (i) 7,507,507 shares (the "Initial Shares") of the Company's common stock, $0.0001 par value per share … |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from SANA graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from SANA graph: Reciprocal relationship from BEAM g… |
| BEAM | Beam Therapeutics Inc. | 72% | the University of California (UCSF), our fusogen technology that we acquired from Cobalt Biomedicine, Inc. (Cobalt), and gene editing technology that we licensed from Beam Therapeutics Inc., among ot… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from SANA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from SANA graph: Reciprocal relationship from MYGN g… |
| MYGN | Myriad Genetics, Inc. | 72% | with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property, the value of such technology, data, or intellectual property to our company may b… |
| SNYNF | Sanofi | 72% | with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property, the value of such technology, data, or intellectual property to our company may b… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from SANA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SANA graph: with or controlled by state actor… |
| ACQUISITIONS-COBALT-BIOMEDICINE-INC | ACQUISITIONS-COBALT-BIOMEDICINE-INC | 62% | aintaining the Company’s intellectual property portfolio, raising capital, and providing general and administrative support for these operations. Liquidity and capital resources The Company is subjec… |
| CELLECT-LLC | CELLECT-LLC | 62% | d to expend significant resources to modify and maintain our business practices in our efforts to comply with such laws and regulations and to otherwise ensure appropriate and lawful use of AI Techno… |
| COBALT-BIOMEDICINE-INC | COBALT-BIOMEDICINE-INC | 62% | of the University of California (UCSF), our fusogen technology that we acquired from Cobalt Biomedicine, Inc. (Cobalt), and gene editing technology that we licensed from Beam Therapeutics Inc., among… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. We coul… |
| USA-LLC | USA-LLC | 62% | aintaining the Company’s intellectual property portfolio, raising capital, and providing general and administrative support for these operations. Liquidity and capital resources The Company is subjec… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SANA-DEBT | Debt stack $82.6M | 90% | Market cache reports total debt of $82.6M. |
| SANA-DEBT-12365 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SANA-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 201 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 |